 |
1 Disease |  |
67 Trials |
|
67 Trials |  |
1555 News |  |
| «12...28293031323334353637383940» |
- || Ad-RTS-hIL-12 / Alaunos Therap
New P2 trial: Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma (clinicaltrials.gov) - Jul 1, 2019
P2, N=30, Recruiting, Sponsor: Ziopharm
- | Libtayo (cemiplimab-rwlc) / Regeneron, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open: A Vaccine (VSV-hIFN?-NIS) with or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma (clinicaltrials.gov) - Jun 27, 2019
P1, N=24, Recruiting, Sponsor: Mayo Clinic
Suspended --> Recruiting
- |||||| Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment open: C-POST: Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov) - Jun 25, 2019
P3, N=412, Recruiting, Sponsor: Regeneron Pharmaceuticals
Suspended --> Recruiting Not yet recruiting --> Recruiting
- ||| Libtayo (cemiplimab) / Sanofi, Regeneron
Alexander Guminski MD on Phase 2 Study Of #Cemiplimab https://t.co/rlSkhyjlmH @Sydney_Uni #Melanoma #SkinCancer #ASCO19 (Twitter) - Jun 25, 2019
- |||| Libtayo (cemiplimab-rwlc) / Regeneron
Trial primary completion date: EMPOWER-Cervical 1: Study of Cemiplimab in Adults With Cervical Cancer (clinicaltrials.gov) - Jun 21, 2019
P3, N=436, Recruiting, Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2022 --> Apr 2023
- |||| Libtayo (cemiplimab-rwlc) / Regeneron
Trial completion date, Trial primary completion date: EMPOWER-lung 1: Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Jun 19, 2019
P3, N=700, Recruiting, Sponsor: Regeneron Pharmaceuticals
Trial primary completion date: Jan 2022 --> Apr 2023 Trial completion date: Sep 2022 --> Feb 2023 | Trial primary completion date: Sep 2022 --> Feb 2023
- | Biomarker, Journal, PD(L)-1 Biomarker, IO Biomarker: What's new in oncodermatology? (Pubmed Central) - Jun 15, 2019
We also have a new anti-BRAF + anti-MEK combination: encorafenib + binimetinib with a good benefit/risk ratio and a particularly favorable safety profile as compared with existing similar combinations. Major steps forward were obtained for locally advanced Merkel cell carcinoma and squamous cell carcinoma with anti-PDL-1 avelumab and anti-PD1 cemiplimab respectively.
- |||| nezastomig (REGN5678) / Regeneron, Libtayo (cemiplimab-rwlc) / Regeneron
New P1/2 trial, IO biomarker: A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors (clinicaltrials.gov) - Jun 2, 2019
P1/2, N=123, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
- |||||||||| Libtayo (cemiplimab-rwlc) / Regeneron
New P3 trial: C-POST: Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov) - May 30, 2019
P3, N=412, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
- || SAR439459 / Sanofi
Enrollment change, Monotherapy: A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - May 24, 2019
P1, N=225, Recruiting, Sponsor: Sanofi
Major steps forward were obtained for locally advanced Merkel cell carcinoma and squamous cell carcinoma with anti-PDL-1 avelumab and anti-PD1 cemiplimab respectively. N=130 --> 225
- || Libtayo (cemiplimab-rwlc) / Regeneron
Biomarker, Enrollment closed, Trial completion date, PD(L)-1 Biomarker, IO biomarker: An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1) (clinicaltrials.gov) - May 20, 2019
P1, N=33, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
N=130 --> 225 Recruiting --> Active, not recruiting | Trial completion date: May 2020 --> Dec 2020
- | Libtayo (cemiplimab-rwlc) / Regeneron, Yervoy (ipilimumab) / BMS
Trial primary completion date: Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer (clinicaltrials.gov) - May 20, 2019
P1, N=24, Recruiting, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Recruiting --> Active, not recruiting | Trial completion date: May 2020 --> Dec 2020 Trial primary completion date: Apr 2019 --> Dec 2019
- | Libtayo (cemiplimab) / Sanofi, Regeneron
Journal: Cemiplimab effective in cutaneous SCC. (Pubmed Central) - May 17, 2019
Trial primary completion date: Apr 2019 --> Dec 2019 No abstract available
- || Libtayo (cemiplimab-rwlc) / Regeneron
New P2 trial: PRIME-CUT: REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer (clinicaltrials.gov) - May 14, 2019
P2, N=20, Recruiting, Sponsor: Mark Stein
- ||| Libtayo (cemiplimab) / Sanofi, Regeneron, Keytruda (pembrolizumab) / Merck (MSD)
#ASCO19 1) 1stL H&N: extreme, taxanes or pembro? 2) HPV vaccination 3) cemiplimab: new standard for non-melanoma? 4) role of induction in nasopharynx? (Twitter) - May 9, 2019
- || Libtayo (cemiplimab-rwlc) / Regeneron
Trial completion date, Trial primary completion date: REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma (clinicaltrials.gov) - May 9, 2019
P1/2, N=150, Recruiting, Sponsor: Regeneron Pharmaceuticals
No abstract available Trial completion date: Oct 2024 --> Jan 2025 | Trial primary completion date: Sep 2024 --> Jan 2025
- | Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment open: Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART (clinicaltrials.gov) - Apr 16, 2019
P1/2, N=45, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial completion date: Oct 2024 --> Jan 2025 | Trial primary completion date: Sep 2024 --> Jan 2025 Not yet recruiting --> Recruiting
- ||| Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment open: CASE: CemiplimAb Survivorship Epidemiology (clinicaltrials.gov) - Apr 16, 2019
P=N/A, N=350, Recruiting, Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Libtayo (cemiplimab-rwlc) / Regeneron
New P2 trial: Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients (clinicaltrials.gov) - Apr 15, 2019
P2, N=94, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
- |||| Libtayo (cemiplimab-rwlc) / Regeneron
Trial completion date, Trial primary completion date, PD(L)-1 Biomarker: EMPOWER-Lung 3: Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer (clinicaltrials.gov) - Apr 9, 2019
P3, N=810, Recruiting, Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Recruiting Trial completion date: Jul 2022 --> Feb 2023 | Trial primary completion date: Jul 2022 --> Feb 2023
- ||| Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, IO biomarker: EMPOWER-lung 4: A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer (clinicaltrials.gov) - Apr 8, 2019
P2, N=28, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
Trial completion date: Jul 2022 --> Feb 2023 | Trial primary completion date: Jul 2022 --> Feb 2023 Recruiting --> Active, not recruiting | N=252 --> 28 | Trial completion date: Jan 2022 --> Apr 2020 | Trial primary completion date: Jan 2022 --> Apr 2020
- || Libtayo (cemiplimab-rwlc) / Regeneron
Trial completion date, Trial primary completion date: R2810-ONC-1620: PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy (clinicaltrials.gov) - Apr 3, 2019
P2, N=137, Recruiting, Sponsor: Regeneron Pharmaceuticals
Recruiting --> Active, not recruiting | N=252 --> 28 | Trial completion date: Jan 2022 --> Apr 2020 | Trial primary completion date: Jan 2022 --> Apr 2020 Trial completion date: May 2021 --> May 2022 | Trial primary completion date: Sep 2020 --> Oct 2021
- | Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
Clinical, Clinical guideline, Review, Journal, Adverse events, Checkpoint inhibition: Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: a Minireview of Current Clinical Guidelines. (Pubmed Central) - Apr 2, 2019
Herein, we review the mechanisms of irAEs and strategies for management of irAEs and highlight similarities as well as differences among clinical guidelines from the National Comprehensive Cancer Network, American Society of Clinical Oncology, Society for Immunotherapy of Cancer, and European Society for Medical Oncology. Understanding these similarities and key differences will facilitate the development and implementation of a practice site-specific plan for the management of irAEs.
- || Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment open: Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma (clinicaltrials.gov) - Apr 2, 2019
P1, N=36, Recruiting, Sponsor: Regeneron Pharmaceuticals
Understanding these similarities and key differences will facilitate the development and implementation of a practice site-specific plan for the management of irAEs. Not yet recruiting --> Recruiting
- ||| Libtayo (cemiplimab) / Sanofi, Regeneron
Clinical: Dr. Olszanski @FoxChaseCancer #skincancer on Patient Selection for Cemiplimab Treatment in CSCC https://t.co/McniJ23pPh via @onclive (Twitter) - Mar 29, 2019
- || rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
Enrollment closed: INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) (clinicaltrials.gov) - Mar 29, 2019
P1/2, N=52, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Sarclisa (isatuximab-irfc) / Sanofi
Trial completion date, Trial primary completion date: Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (clinicaltrials.gov) - Mar 28, 2019
P1/2, N=105, Recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting Trial completion date: Jul 2023 --> Mar 2021 | Trial primary completion date: Jul 2023 --> Mar 2021
- || Sarclisa (isatuximab-irfc) / Sanofi
Trial completion date, Trial primary completion date: Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies (clinicaltrials.gov) - Mar 26, 2019
P1/2, N=134, Recruiting, Sponsor: Sanofi
Trial completion date: Jul 2023 --> Mar 2021 | Trial primary completion date: Jul 2023 --> Mar 2021 Trial completion date: Aug 2022 --> Jul 2021 | Trial primary completion date: Aug 2022 --> Jul 2021
- || Libtayo (cemiplimab-rwlc) / Regeneron
New P1 trial: Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma (clinicaltrials.gov) - Mar 26, 2019
P1, N=36, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
- || Hiltonol (poly-ICLC) / Oncovir
Trial completion date, Trial primary completion date: In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol (clinicaltrials.gov) - Mar 13, 2019
P2, N=100, Recruiting, Sponsor: Oncovir, Inc.
Trial completion date: Aug 2022 --> Jul 2021 | Trial primary completion date: Aug 2022 --> Jul 2021 Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2018 --> Jun 2021
- || Sarclisa (isatuximab-irfc) / Sanofi
Trial completion date, Trial primary completion date: A Study of Isatuximab-based Therapy in Participants With Lymphoma (clinicaltrials.gov) - Mar 12, 2019
P1/2, N=130, Recruiting, Sponsor: Sanofi
Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2018 --> Jun 2021 Trial completion date: Jun 2022 --> Jan 2023 | Trial primary completion date: Jun 2022 --> Jan 2023
- ||| SAR441000 / Sanofi, BioNTech
New P1 trial, Monotherapy: A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 11, 2019
P1, N=264, Recruiting, Sponsor: Sanofi
- ||||| Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Monotherapy: EMPOWER-Lung 2: REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer (clinicaltrials.gov) - Mar 6, 2019
P3, N=5, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
Trial completion date: Jun 2022 --> Jan 2023 | Trial primary completion date: Jun 2022 --> Jan 2023 Recruiting --> Active, not recruiting | N=585 --> 5 | Trial completion date: Mar 2023 --> Nov 2020 | Trial primary completion date: Mar 2023 --> Nov 2020
- | SAR439459 / Sanofi
Trial completion date, Monotherapy: A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Feb 18, 2019
P1, N=130, Recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting | N=585 --> 5 | Trial completion date: Mar 2023 --> Nov 2020 | Trial primary completion date: Mar 2023 --> Nov 2020 Trial completion date: Jul 2021 --> Mar 2022
- |||||| Libtayo (cemiplimab-rwlc) / Regeneron
New trial: CASE: CemiplimAb Survivorship Epidemiology (clinicaltrials.gov) - Feb 10, 2019
P, N=350, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
- |||||||||| Libtayo (cemiplimab-rwlc) / Regeneron
New P3 trial, PD(L)-1 Biomarker: EMPOWER-Lung 3: Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer (clinicaltrials.gov) - Jan 19, 2019
P3, N=690, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals
- || Sarclisa (isatuximab-irfc) / Sanofi
Trial completion date, Trial primary completion date: Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (clinicaltrials.gov) - Jan 16, 2019
P1/2, N=105, Recruiting, Sponsor: Sanofi
Trial completion date: Jul 2021 --> Mar 2022 Trial completion date: Aug 2022 --> May 2023 | Trial primary completion date: Aug 2022 --> May 2023
- ||| Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment change, Trial completion date: EMPOWER-CSCC-1 : Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov) - Jan 14, 2019
P2, N=266, Recruiting, Sponsor: Regeneron Pharmaceuticals
Trial completion date: Aug 2022 --> May 2023 | Trial primary completion date: Aug 2022 --> May 2023 N=182 --> 266 | Trial completion date: Jun 2020 --> Aug 2021
- || Libtayo (cemiplimab-rwlc) / Regeneron
Biomarker, Enrollment closed, Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1) (clinicaltrials.gov) - Jan 11, 2019
P1, N=50, Active, not recruiting, Sponsor: Regeneron Pharmaceuticals
N=182 --> 266 | Trial completion date: Jun 2020 --> Aug 2021 Recruiting --> Active, not recruiting | Trial completion date: Jun 2020 --> Oct 2019 | Trial primary completion date: Jun 2019 --> Mar 2019
- || Libtayo (cemiplimab-rwlc) / Regeneron, Yervoy (ipilimumab) / BMS
Enrollment open: Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer (clinicaltrials.gov) - Jan 8, 2019
P1, N=24, Recruiting, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
Recruiting --> Active, not recruiting | Trial completion date: Jun 2020 --> Oct 2019 | Trial primary completion date: Jun 2019 --> Mar 2019 Not yet recruiting --> Recruiting
- ||| cavrotolimod (AST-008) / Exicure, Bluejay Therap
Enrollment open, PD(L)-1 Biomarker, IO biomarker: Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors (clinicaltrials.gov) - Dec 27, 2018
P1b/2, N=81, Recruiting, Sponsor: Exicure, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Libtayo (cemiplimab-rwlc) / Regeneron
New P1/2 trial: Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART (clinicaltrials.gov) - Dec 26, 2018
P1/2, N=45, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- ||| ISA101 / ISA Pharma
Enrollment open: OpcemISA: A Randomized Phase 2 Study of Cemiplimab (clinicaltrials.gov) - Dec 17, 2018
P2, N=164, Recruiting, Sponsor: ISA Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Sarclisa (isatuximab-irfc) / Sanofi
Enrollment open: A Study of Isatuximab-based Therapy in Participants With Lymphoma (clinicaltrials.gov) - Dec 11, 2018
P1/2, N=130, Recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Sarclisa (isatuximab-irfc) / Sanofi
New P1/2 trial: A Study of Isatuximab-based Therapy in Participants With Lymphoma (clinicaltrials.gov) - Dec 6, 2018
P1/2, N=130, Not yet recruiting, Sponsor: Sanofi
- ||||| Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment change, Trial completion date, Trial primary completion date: EMPOWER-lung 1: Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Nov 5, 2018
P3, N=700, Recruiting, Sponsor: Regeneron Pharmaceuticals
Not yet recruiting --> Recruiting N=300 --> 700 | Trial completion date: Sep 2021 --> Sep 2022 | Trial primary completion date: Sep 2021 --> Sep 2022
- | Hiltonol (poly-ICLC) / Oncovir
New P1/2 trial: Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1 (clinicaltrials.gov) - Oct 25, 2018
P1/2, N=60, Recruiting, Sponsor: Oncovir, Inc.
- || Sarclisa (isatuximab-irfc) / Sanofi
Trial completion date, Trial primary completion date: Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (clinicaltrials.gov) - Oct 25, 2018
P1/2, N=105, Recruiting, Sponsor: Sanofi
N=300 --> 700 | Trial completion date: Sep 2021 --> Sep 2022 | Trial primary completion date: Sep 2021 --> Sep 2022 Trial completion date: Jan 2021 --> Aug 2022 | Trial primary completion date: Jan 2021 --> Aug 2022
- | Libtayo (cemiplimab-rwlc) / Regeneron
Enrollment open: REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma (clinicaltrials.gov) - Oct 5, 2018
P1/2, N=150, Recruiting, Sponsor: Regeneron Pharmaceuticals
Trial completion date: Jan 2021 --> Aug 2022 | Trial primary completion date: Jan 2021 --> Aug 2022 Not yet recruiting --> Recruiting
- | Libtayo (cemiplimab-rwlc) / Regeneron
New P1/2 trial: REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma (clinicaltrials.gov) - Sep 30, 2018
P1/2, N=150, Not yet recruiting, Sponsor: Regeneron Pharmaceuticals